Watson Pharmaceuticals, Inc. WPI today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc. AMRIX is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal conditions.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in